- Home
- APLT vs WNEB Comparison
APLT vs WNEB Comparison
Compare APLT & WNEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- WNEB
- Stock Information
- Founded
- APLT 2016
- WNEB 1853
- Country
- APLT United States
- WNEB United States
- Employees
- APLT N/A
- WNEB 335
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- WNEB Savings Institutions
- Sector
- APLT Health Care
- WNEB Finance
- Exchange
- APLT Nasdaq
- WNEB Nasdaq
- Market Cap
- APLT 178.6M
- WNEB 246.1M
- IPO Year
- APLT 2019
- WNEB N/A
- Fundamental
- Price
- APLT $0.26
- WNEB $12.10
- Analyst Decision
- APLT Buy
- WNEB Buy
- Analyst Count
- APLT 5
- WNEB 2
- Target Price
- APLT $4.13
- WNEB $11.00
- AVG Volume (30 Days)
- APLT 24.7M
- WNEB 40.8K
- Earning Date
- APLT 11-13-2025
- WNEB 10-28-2025
- Dividend Yield
- APLT N/A
- WNEB 2.31%
- EPS Growth
- APLT N/A
- WNEB 27.15
- EPS
- APLT N/A
- WNEB 0.66
- Revenue
- APLT $1,000,000.00
- WNEB $79,080,000.00
- Revenue This Year
- APLT N/A
- WNEB N/A
- Revenue Next Year
- APLT $5,935.35
- WNEB $7.48
- P/E Ratio
- APLT N/A
- WNEB $18.45
- Revenue Growth
- APLT N/A
- WNEB 9.08
- 52 Week Low
- APLT $0.22
- WNEB $7.63
- 52 Week High
- APLT $10.48
- WNEB $12.80
- Technical
- Relative Strength Index (RSI)
- APLT 27.74
- WNEB 60.66
- Support Level
- APLT $0.26
- WNEB $11.32
- Resistance Level
- APLT $0.40
- WNEB $12.07
- Average True Range (ATR)
- APLT 0.12
- WNEB 0.27
- MACD
- APLT -0.07
- WNEB 0.02
- Stochastic Oscillator
- APLT 4.83
- WNEB 79.61
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.